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Summary.-The influence of human serum albumin (HA) on the biological effects of
13 chemotherapeutic agents was studied in vitro in the human leukaemia cell line
MOLT-3. On the basis of changes in biological activity influenced by HA, these drugs
may be divided into three types. Type I agents include cis-diamminedichloro-
platinum (II), 4'-(9-acridinylamino)methanesulphon-m-anisidide, neocarzino-
statin, nitrogen mustard, adriamycin, daunorubicin and mitomycin C-drugs
whose biological activities are reduced in the presence of HA. The biological
activities of Type II drugs (cytosine arabinoside, fluorouracil and actinomycin D) are
not influenced by HA. The biological activities of Type III drugs (bleomycin, vin-
cristine and vinblastine) are increased in the presence of HA. These results indicate
that serum HA interferes in vitro with certain anticancer agents in terms ofbiological
activity and, probably, clinical effectiveness. HA-drug interaction may be a major
factor governing the pharmacology of Type I anticancer agents in man.
How TO DELIVER an effective concen-
tration of an anticancer agent to its site of
action is one of the most important con-
siderations in cancer chemotherapy. It is
thought that only free drugs (not bound
to blood constituents) can pass through
the capillary walls ofblood vessels to exert
biological activity at their specific sites of
action (Koch-Weser & Sellers, 1976). The
interaction of anticancer drugs with blood
constituents, particularly with serum
albumin, should have a major influence on
drug pharmacology and efficiency.
The binding of certain anticancer drugs
to plasma protein has been quantified in
both in vitro and in vivo systems (Linford,
1961; Donigian & Owellen, 1973; DeConti
et al., 1973; Cysyk et al., 1977), but reports
on the role of such binding in altering
biological activity and therapeutic effects
have been few. Dichloromethotrexate
(DCM), an antifolate, was shown to have
a higher chemotherapeutic index in mice
than methotrexate (MTX) (Goldin et al.,
1957; Vogel, 1961). Reevaluation of inter-
mittent schedules revealed that much
larger doses of DCM than of MTX were
tolerated in man without leucovorin
rescue (Fernbach et al., 1979). Serum
levels of DCM measured by RIA were
comparable to MTX levels on a molar
basis. Using a human cell-culture system
containing human serum albumin (HA)
we demonstrated that man's ability to
tolerate much higher doses of IDCM than
of MTX could be explained, at least in
part, by DCM's higher affinity to HA,
resulting in a decreased unbound fraction,
the active cytotoxic form (Takahashi
et al., 1979).
These findings indicated the need for
studying the interaction between HA and
anticancer agents, and prompted us to
extend our study of HA-drug interaction
to include 13 anticancer agents currently
used in man.
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MATERIALS AND METHODS
Cell lines.-A human leukaemia cell line,
MOLT 3 (Minowada et al., 1972) was used for
the experiment. The cells were maintained in
suspension in culture flasks containing RPMI
1640 medium (Gibco, Grand Island, NY) with
10% heat-inactivated foetal calf serum (FCS)
and antibiotics (penicillin 100 iu/ml and
streptomycin 100 jug/ml) and fed with fresh
medium 3 times a week. The experimental
design was as described previously (Takahashi
et al., 1979). Briefly, when cells, 15 x 105/ml,
were transferred to a culture tube (No 3033,
Falcon, Oxnard, CA) containing 10 ml of the
culture medium and incubated at 37°C on
Day 0, they grew exponentially from Day 1
to Day 4. In the presence of 2-5 g/dl HA
(No A-2386, Sigma Chemical Co., St Louis,
MO) cells grew exponentially with a minimal
inhibition of cell growth by Day 4, and this
concentration was used for the entire experi-
ment. This HA concentration is also close to
the normal serum albumin concentration in
man (3 5-5 5 g/dl) which makes a meaningful
extrapolation to an in vivo system possible.
Drugs.-The 13 drugs studied were dauno-
rubicin (DNR, supplied by National Cancer
Institute, Bethesda, MD) adriamycin (ADM,
Adria Laboratories, Inc., Columbus, OH)
4'(9-acridinylamino)methanesulphon-m-anisi-
dide (AMSA, supplied by National Cancer
Institute, Bethesda, MD) neocarzinostatin
(NCS, supplied by National Cancer Institute,
Bethesda, MD) bleomycin (BLM, Bristol
Laboratories, Syracuse, NY) mitomycin C
(MMC, Bristol Laboratories, Syracuse, NY)
actinomycin D (AMD, Merck Sharp & Dohme,
Westpoint, PA) nitrogen mustard (HN2,
Merck Sharp & Dohme) cytosine arabinoside
(Ara-C, The Upjohn Company, Kalamazoo,
MI) fluorouracil (FU, Roche Laboratories,
Nutley, NJ) vincristine (VCR, Eli Lilly and
Company, Indianapolis, IN) vinblastine
(VBL, Eli Lilly and Company) and cis-
diamminedichloroplatinum (DDP, supplied
by National Cancer Institute, Bethesda, MD).
All drugs except AMSA, which was diluted in
5% dextrose solution (Abbott, NorthChicago,
IL) were diluted with phosphate-buffered
saline (PBS, Gibco) and0-I ml ofeach solution
was added to culture tubes containing 10 ml
of culture medium and 15 x 105/ml cells on
Day 0. The culture medium, RPMI 1640,
which contained 10% FCS, antibiotics and
2-5 g/dl HA, was sterilized by passage through
a 0'45jum filter membrane (Nalgene Sybron
Corp., Rochester, NY). The culture medium
with or without HA and the drug solutions
were prepared freshly before each experiment.
Evaluation of HA-drug interaction.-In
order to evaluate the HA-drug interaction,
ID50 and ID90 values were compared for each
drug in culture medium with or without HA.
The ID50 and ID90 values were defined as
concentrations of drug which produced 50%
and 90% inhibition of viable cell growth as
determined by trypan-blue dye exclusion on
Day3 when compared to controlwithoutdrug.
Effect ofprior exposure to HA.-In order to
test whether prior exposure of cells to HA
influenced drug sensitivity, cells were grown
in the presence of 2-5 g/dl of HA for 3 days.
The cells were then washed twice with RPMI
1640 to remove HA and resuspended in
the medium. These cells were exposed to
ID50 of the drugs for 3 days and the per-
centage inhibition was compared with the
numbers of cells which were processed simi-
larly but without HA. All studies were done
in triplicate and experiments were repeated
at least 3 times.
RESULTS AND DISCUSSION
The ID50 and ID90 values for each drug
in the presence and absence of 2-5 g/dl HA
are shown in the Table. These drugs were
divided into 3 types on the basis of
changes in biological activity influenced
by HA. In Type I compounds (DDP,
AMSA, NCS, HN2, ADM, DNR and MMC)
biological activities were definitely re-
duced by the presence of 2-5 g/dl HA
(Fig. 1). Thus the ID5o concentrations of
DDP, AMSA, NCS, HN2, ADM, DNR and
MMC were, respectively, 4-l-, 2-8-, 2-7-,
2-1-, 1-8-, 1P7- and 1'5-fold higher than
those in the medium containing no HA.
On an ID90 basis, these values were 4 3-,
2-6-, 3*0-, 19-, 1.9-, 2-0- and 1-5-fold,
respectively. HA in the medium did not
interfere with the biological activities of
Type II compounds (Fig. 1) which in-
cluded Ara-C, FU and AMD. Type III
compounds (BLM, VCR and VBL) were
those in which biological activities were
clearly increased in the presence of HA
(Fig. 1). The decreased biological activity6041 1. TAKAHASHI ET AL.
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FIG. 1.-Influence ofhuman serum albumin on biological activity of 3 anticancer agents. -I-, cul-
ture medium without human serum albumin; --O--, culture medium containing human serum
albumin (2-5 g/dl); bar, s.d.
seen in Type I compounds may either be
due to HA-drug binding or to other
mechanisms, such as inactivation of drugs
by HA and decrease in entry ofdrugs into
the cell. Cells pretreated with 2-5 g/dl HA
in the medium from Day -3 to Day 0
were found to be more sensitive to each
drug than the non-HA-pretreated cells,
and did not result in decreased biological
effects of Type I drugs or, indeed, of any
other agents tested (Fig. 2). These results
suggested that HA did not interact
directly with cell membranes to prevent
entry of Type I drugs into cells, and that
the biological activities of these drugs
were reduced by direct HA-drug inter-
action in the medium. Previous work from
this laboratory revealed that equitoxic
concentrations of DCM and MTX were
bound to HA about 85% and 50%,
respectively (Takahashi et al., 1979).
DDP was reported to be highly bound to
plasma protein (DeConti et al., 1973;
LeRoy et al., 1979) and to exert cytotoxic
activity in filterable form only (Patton
et al., 1978). AMSA, which is a DNA
binder similar to other acridines, was
found to bind to rat plasma protein, with
about 50% binding with plasma protein
2 h after drug administration (Cysyk et al.,
1977). On the other hand, pyrimidine
analogues do not generally bind to plasma
protein (Mihich, 1973; Dixon & Adamson,
1965). It appears, therefore, that HA's
influence on biological activity of Type I
compounds is related to moderate to high
degrees of binding of drugs to HA in the
culture medium. The lack of interaction
of Type II compounds is in accord with
reports that these compounds do not bind
with HA.
It has been reported that BLM has a
rapid renal clearance and does not bind
with plasma protein (Sikic et al., 1978).
Donigian & Owellen (1973) have shown
that, at physiological concentrations of
serum protein, 75% ofVCR and VBL bind
to protein, and are absorbed 10x moreI. TAKAHASHI El' AL.
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FIG. 2. Effects of prior exposure to human serum albumin on the chemotherapeutic susceptibility of
MOLT 3 cells. The growth inhibition of untreated cells is represented as unity.
extensively to oa- and fl-globulins than to
albumin on a mol/g basis. Therefore, low
binding ofvinca alkaloids with HA is con-
sistent with inability of HA to decrease
the biological effects of the compounds.
The susceptibility of cells exposed to HA
before the addition of chemotherapeutic
agents tended to be more pronounced
with Type III agents (Fig. 2). The data
suggest that, for Type III agents, the
direct inhibitory effects on the cell
potentiated by HA were more pronounced
than any effects produced by the decrease
in available free drug. It is also possible
that biological changes produced by the
macromolecule onintracellular metabolism
and/or on the cell membrane were respon-
sible for this observation.
We found no clear correlation between
molecular weight of a drug and the in-
fluence of HA on the biological effects of
the drug. Since the biological activity of
DDP, which has a lower molecular weight
than other drugs evaluated in this study,
is most influenced by HA, the molecular
weight ofthe drug does not appear to be a
determining factor in HA-drug inter-
action. The drugs known to bind with
DNA tend to be influenced by HA, but
there are some exceptions (e.g. NCS).
Since the parent medium contains 10%
FCS and antibiotics, it is possible that calf
serum albumin interacts with Type I
compounds. However, it is estimated that
the calf serum albumin constituted only
12-15% ofHA. All experiments were done
in the presence of 10% FCS and defined
concentrations of antibiotics, and signifi-
cant differences were recognized in the
shapes of the drug-produced response
curves with or without HA (Fig. 1).
The albumin-anticancer agent inter-
action in vitro may have a bearing on at
least 2 areas. First, the marked loss in
biological activity produced by HA on
Type I compounds may occur in vivo in
respect to cell-kill effects and, probably,
clinical effectiveness. In such in vivo
circumstances the HA-drug complex
might be displaced by unrelated drugs
(Koch-Weser & Sellers, 1976). The dis-
placement of the anticancer agent by
unrelated agents, particularly of a drug
with high binding capacity, poses an
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important problem, because asmall change
in binding will increase the proportion
of free drug and may produce in-
creased clinical toxicity. Thus, the
administration of Type I drugs to patients
with hypoalbuminaemia, and the con-
comitant administration of unrelated
drugs when necessary, requires close
clinical monitoring. Second, the inter-
action may be relevant to the clinical
effects of the drug given by different
schedules. Drug administration has been
scheduled either empirically or on the
basis of pharmacokinetics and cell-kill
kinetics of the drug. In order to achieve
the maximal cell kill by an S-phase-
specific drug it has been proposed that
such a drug be administered not only in
an adequate dose, but also with sufficient
frequency (Clarkson, 1974). The con-
tinuous infusion of Ara-C is rational in
respect to its cell-kill kinetics and to its
lack ofinteractionwith HA. Onthe basisof
HA-drug interaction, the drug with high
HA-binding capacity may be considered
for administration by repeated i.v. bolus
rather than by continuous infusion, be-
cause continuous infusion may cause
successive uptake by plasma protein,
leaving little free active drug (Koch-
Weser & Sellers, 1976). In this context,
repeated i.v. bolus administration may be
considered for Type I drugs in order to
achieve effective concentrations of free
drugs. We noted recently that patients
tolerated NCS given by continuous 24h
infusion at a dose 3 x that given by
short 2h infusion (Ohnuma et al., 1978).
These observations may be explained
partly by an HA-NCS interaction in
plasma.
The results of in vitro drug studies with
with cultured cells cannot hastily be
extrapolated to the clinical setting without
consideration of in vivo pharmacokinetic
barriers. Nevertheless, albumin-binding is
expected significantly to influence absorp-
tion, transport, distribution and excretion
of the Type I compounds, in a complex
fashion. We consider the HA-anticancer-
agent interaction as one of the major
factors governing the pharmacology ofthe
Type I drug in man.
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